Cite Score:
0.7
CITE SCORE SCOPUS

Efficacy of Ascorbic Acid Supplementation in Relief of Symptoms Due to Febrile Upper Urinary Tract Infection in Children, a Clinical Trial and Hospital Based Study

AUTHORS

Parsa Yousefichaijan 1 , Ali Ahmad Goudarzi 2 , Masoud Rezagholizamenjany ORCID 2 , * , Manijeh Kahbazi 3 , Mohammad Rafeie 4 , Ali Arjmand Shabestari 3 , Fakhreddin Shariatmadari 3 , Hassan Taherahmadi 3

1 Department of Pediatric Nephrology, AmirKabir Hospital, Arak University of Medical Sciences, Arak, Iran

2 School of Medicine, Arak University of Medical Sciences, Arak, Iran

3 Department of Pediatric, Arak University of Medical Sciences, Arak, Iran

4 Department of Biostatistics, Arak University of Medical Sciences, Arak, Iran

How to Cite: Yousefichaijan P, Ahmad Goudarzi A , Rezagholizamenjany M, Kahbazi M, Rafeie M, et al. Efficacy of Ascorbic Acid Supplementation in Relief of Symptoms Due to Febrile Upper Urinary Tract Infection in Children, a Clinical Trial and Hospital Based Study, Arch Pediatr Infect Dis. 2018 ; 6(4):e57071. doi: 10.5812/pedinfect.57071.

ARTICLE INFORMATION

Archives of Pediatric Infectious Diseases: 6 (4); e57071
Published Online: July 23, 2018
Article Type: Research Article
Received: July 23, 2017
Revised: March 6, 2018
Accepted: March 11, 2018
Crossmark

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Urinary tract infections (UTIs) as a urological disorder occur in 1% - 3% of females and 1% of males. This disease can induce severe complications such as pyelonephritis.

Objectives: The current study aimed to evaluating the efficacy of vitamin C supplementation on UTI in children.

Methods: The current clinical trial study was conducted on 152 female children with UTI admitted to Amir-Kabir hospital, Arak, Iran. The cases were randomly divided, based on blocked groups, into two treatment and control groups (76 patients in any group). The subjects were matched in terms of age, gender, and clinical signs and symptoms. The control group received only routine treatment of UTI, while the treatment group, in addition to the routine treatment received oral vitamin C supplementation tablet, for a 14-day period.

Results: Dysuria, urine incontinence, fever, urinary urgency, and dribbling occurred significantly earlier in vitamin C supplemented individuals than the control ones, while abdominal pain, dimercaptosuccinic acid (DMSA) scan, and recurrent UTI were not different between the two groups.

Conclusions: Vitamin C supplementation can control the symptoms of urinary tract infections, including fever, dysuria, urinary urgency, and dribbling urine.

Keywords

Urinary Tract Infection Vitamin C Supplementation Children Urinary Symptoms

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

1. Background

Urinary tract infections (UTIs) as the most common urological disease and the 2nd prevalent infection in children after viral flu, affect male and female children in pediatric clinics. This condition is treated with routine antibiotics including ceftriaxone, cefixime, and untreated UTIs lead to pyelonephritis (1-3). The symptoms of pyelonephritis include pain of back, flank or abdomen, nausea, malaise, vomiting, and, diarrhea, but fever may be the only manifestation (4, 5). Also nonspecific symptoms may be observed in newborns, including irritability, poor feeding, weight loss, and jaundice (6-8). Pyelonephritis as the most common serious bacterial infection occurs in infants lower than 24 months of age, and they have fever without an obvious focus (9-11). These symptoms indicate a bacterial infection in upper urinary tract system (12, 13). Acute pyelonephritis can result in renal injury and termed pyelonephritis scaring. Escherichia coli are the cause of infection in 75% - 90% of female cases followed by Klebsiella and Proteus species (6, 10, 14). Vitamin C supplementation is involved in neurotransmitter metabolism, cholesterol metabolism, and the biosynthesis of carnitine. In this reaction, vitamin C supplementations maintain the iron and copper atoms and cofactors of the metalloenzymes, in a reduced state. In addition, it is an important antioxidant in the aqueous of the body (15, 16). Vitamin C supplementations deficiency reduces cellular immunity and increase duration of some diseases (11, 17). Unfortunately, to the authors` best knowledge, there were few studies and only one study was completely related (18) and evaluated the effectiveness of vitamin C supplementations in treating UTIs. Appropriate treatment can reduce kidney scar; therefore, the application of medicinal and nonmedicinal substances to prevent kidney damage are useful.

2. Objectives

Vitamin C supplementation is a nutrient that plays a role in the improvement of the urinary system function; the current study aimed at evaluating the use of vitamin C supplementation to treat UTIs and pyelonephritis and their symptoms.

3. Methods

The current clinical trial was conducted on 152 female patients with positive UTIs and consent to participate in research projects. Subjects with congenital and acquired renal abnormality, no consent to use their personal data in the study, and the ones that for any reasons wanted to leave the study were excluded. The subjects were randomly divided into two groups of treatment and control each with 76 patients; this division was based on blocked groups. The patients in the two groups were matched in terms of age, gender, and clinical symptoms including fever, dysuria, and frequency. Urinary symptoms on the 2nd day of admission and urine culture in 10 days after admission were evaluated. The two groups were given routine antibiotic regimen for UTI (Parenteral treatment with ceftriaxone 50 - 75 mg/kg/day/IV in two divided doses for admitted patients followed by cefixime 8 mg/kg/day/per oral in two divided doses for outpatients for 14 days). In the treatment group, subjects were treated with vitamin C supplementation, 250 mg/ day for 14 days in addition to routine treatment UTI and the control group received placebo and routine treatment of UTIs. Subjects were followed by technetium-labeled dimercaptosuccinic acid (DMSA) scan. The course of resolution of frequency, dysuria, abdominal pain, malodorous, dribbling, fever, and urgency were compared in the two groups; these clinical manifestations were observed and mentioned by interns and parents of patients, improvement and relief of fever, dysuria, abdominal pain, urgency, urinary dribbling, and incontinence were measured as days after improvement on these manifestations in the subjects. Urine culture of children was performed one week, as well as one, two, and three months after the termination of treatment.

Sample size was determined based on previous studies (18) and patients were selected by convenience sampling method; totally, 76 subjects were included in the treatment group 76 in the control group. They were diagnosed with positive UTI and their age range was 5 - 12 years. The treatment and control groups comprised of patients referred to the hospital and diagnosed with UTIs by urine culture (UC). Method of allocation of the subjects in the study was randomized; double blind, and in phase II of clinical trials, in addition, parallel assignment was used. It was observed that Vitamin C had significant effect on symptoms of UTI. For the study blinding, there were two groups of list numbers and patients were select from one of them and allocated into the interventional or control groups and patients or doctors did not know the patients of the two groups.

3.1. Ethical Considerations

Ethical committee of Arak University of Medical Sciences approved the study protocol. Also, the study was registered in the Iranian registry of clinical trials (IRCT) (No. IRCT2015073113366N5).

3.2. Statistical Analysis

Data analysis was conducted by Chi-square and t independent test. In addition, logistic regression analysis was used with the significance level of <0.05.

4. Results

Overall, the follow-up course was not significantly different between the groups; in treatment group was 6.1 ± 2.48 days and in the control group was 5.5 ± 2.014 days (P = 0.14). Also, overall prevalence of fever was 96.7%, which was 98.7% and 94.7% in the control and the treatment groups, respectively (P = 0.2). Also, overall dysuria was 84.8%; while 85.5% and 88% in the control and treatment groups, respectively (P = 0.4). The overall abdominal pain was 87.4%; it was 88.2% and 86.7% in the control and treatment groups, respectively (P = 0.8). The overall frequency was 84.8%; also, 85.5% and 84% in the control and treatment groups, respectively (P = 0.014). The overall urgency was 74.2%; also, 82.9% and 65.3% in the control and treatment groups, respectively (P = 0.8). The overall urinary incontinence was 76.2%; also, 77.6% and 74.7% in the control and treatment groups, respectively (P = 0.7). The overall urine dribbling was 68.2%; it was 71.7% and 65.3% in the control and treatment groups, respectively (P = 0.4). Therefore, except the urgency, all other variables were appropriately overlapping with respect to the reception (Table 1).

Table 1. The Prevalence of Pyelonephritis Symptoms in Percentage in the Study Groups a
VariableTreatmentControlTotalP-Value
Fever0.2
Positive94.798.796.7
Negative5.31.33.3
Dysuria0.4
Positive8892.190.1
Negative127.99.9
Urinary infection frequency0.8
Positive8485.584.8
Negative1614.515.2
Abdominal pain0.8
Positive86.788.287.4
Negative13.311.812.6
Urinary urgency0.014
Positive65.382.974.2
Negative34.717.125.8
Urinary incontinence0.7
Positive74.477.676.2
Negative25.622.423.8
Urine switching0.4
Positive65.371.768.2
Negative34.728.331.8

a All values represented as No. (%).

The average improvement of fever in the control group was 3.96 ± 2.08 days and in treatment group was 2.06 ± 1.29 days that showed a significant difference between the groups (P = 0.001); also, interruption of fever occurred 32 hours earlier in the treatment group, improvement of dysuria was 4.08 ± 2.96 days in the control and 3.99 ± 2.27 days in the treatment groups (P = 0.012). Relief of abdominal pain in the control group was 3.57 ± 3.84 days and 3.13 ± 2.46 days in the treatment group indicating a significant difference between the groups (P = 0.4). Improvement of urgency was 3.96 ± 2.97 days in the control and 2.6 ± 2.76 days in the treatment groups (P = 0.004). Urine dribbling improvement was 3.74 ± 3.64 days in the control and 2.75 ± 2.58 days in the treatment groups (P = 0.022) and urinary incontinence improvement was 4.04 ± 3.61 days in the control and 3.2 ± 3.27 days in the treatment group (P = 0.099) (Table 2). In addition, relief of these complications occurred earlier in the treatment group rather than the control group. Interruption of fever and urgency occurred 32 hours earlier, and the control of dysuria and urine dribbling occurred 24 hours earlier in the treatment group rather than the control group (Table 3). Also, regarding UC in 24 hours, one positive case in the control and 0 in the treatment groups were found (P = 0.99) and regarding positive UC 7 - 10 days after treatment, 13 cases in the control and seven in the treatment groups were observed; therefore, there were no significant differences in the two group before and after the treatment (P = 0.24) (Table 4).

Table 2. Comparing the Mean of Days for Improvement of Clinical Symptoms in the Two Groups a
VariablesAverageStandard DeviationProbability ValueMean Difference
Fever
Control3.962.080.001-1.36
Treatment2.61.29
Dysuria
Control4.082.960.012-1.09
Treatment2.992.27
Urinary frequency
Control4.373.280.1-0.08
Treatment3.562.87
Abdominal pain
Control3.573.840.4-0.43
Treatment3.132.46
Urinary urgency
Control3.962.970.004-1.36
Treatment2.62.76
Urine switching
Control3.743.610.0550-.99
Treatment2.752.58
Urinary incontinence
Control4.043.320.099-0.89
Treatment3.23.27

a All values represented as No. (%).

Table 3. Patients by Fever, Dysuria, Frequency, Abdominal Pain, Urgency, Incontinence, and Dribbling in a 14-Day Follow-up in the Study Groups a
Fever bDysuria cFrequency cAbdominal Pain cUrgency cIncontinence cDribbling c
DayControlVitamin CControlVitamin CControlVitamin CControlVitamin CControlVitamin CControlVitamin CControlVitamin C
+-+-+-+-+-+-+-+-+-+-+-+-+-+-
17517427066610652163136796511631349275917562054224927
27156214631352246323571962145719571941355620453153234531
354223442473037395224373945313650433331454333294739372947
436401660324424524234274935412353344224524036235329472650
525415712848868284819572452156128416603145156124521759
6195727424525712254136321551363235310661957146223531363
71165274175957120561363175996719571066165013631660769
837317512644721561106610665711660373136311651363670
9175175868472106696767047286837310668681165472
10175175571373571868472472769248687691066373
1117507647237347257117537327427769769571472
12175076076076472472076175175175274274472274
13076076076076175175076076076175175274274175
14076076076076175175076076076175076274175076

a All values represented as No. (%).

b P-values = 0.05.

c P-values = 0.001.

Table 4. Distribution of Urine Culture in the Two Groups a
VariableTreatmentControlTotalP-Value
48-Hour UC0.99
Positive0 (0.0)1 (1.3)1 (0.7)
Negative76 (100)75 (98.7)150 (3.99)
UC, 7 - 10 Days after treatment0.23
Positive7 (9.3)13 (17.1)20 (13.2)
Negative68 (90.7)63 (82.9)131 (86.8)

a All values represented as No. (%).

5. Discussion

The current study aimed at considering the effect of vitamin C supplementation on the development of UTIs in children. Accordingly, there was no difference in DMSA scan and UC of children treated with vitamin C supplementation and antibiotics and the ones receiving only antibiotics. Since the current study observed the effect of vitamin C supplementation in the earlier improvement of fever, dysuria, urinary urgency, and urine dribbling; therefore, to treat patients with pyelonephritis-presented early in the disease- vitamin C supplementation can be used to improve the symptoms and it seems that intake of vitamin C supplementation has significant effect UTI manifestations and reduced hospitalization period; contributing to the current study results, several studies on kidney stones are discussed as follows:

Zarinfar et al., in a study on the effect of vitamin C supplementation on the treatment of UTI observed that vitamin C supplementation, as a supplementary drug, improved some pyelonephritis symptoms such as fever and dysuria and decreased hospitalization period (18) that their results were similar to those of the current study. Montorsi et al., in a study enrolled 42 consecutive females with recurrent UTIs and treated with 120 mg cranberries plus 750 mg vitamin C supplementation thrice daily for 20 consecutive days reported negative urinary analysis (UA) and UC and absence of symptoms. They found no major side effects in the follow-up of 26 patients at three-month and 22 patients at six-month (14, 19); but in the current study, the side effects of vitamin C were not evaluated. In another study by Nseir et al., on the association between vitamin D and UTIs in a period of three years, 93 females that were premenopausal with the history of recurrent UTI from the Infectious Diseases Unit were enrolled. They concluded that recurrent UTIs in premenopausal females were associated with vitamin D deficiency (13), but the current study was conducted on children and no association was observed. In a study by Fowler et al., in 1:1:1 ratio, they randomized 24 children admitted to the intensive care unit affected by sepsis, receiving IV ascorbic acid every six hours for four days. They concluded that IV infusion of ascorbic acid was safe and well tolerable (20). Yousefichaijan et al., concluded that zinc supplementation had a positive efficacy in the relief of severe UTIs symptoms (21). Also, in another study by Yousefichaijan et al., on vitamin E and UTIs they observed that vitamin E in UTIs had statistically significant ameliorating impact on the signs and symptoms (15); also, in the current study the effect of vitamin C was approved. Bannwart et al., concluded that vitamin C supplementation cannot be recommended to lower urinary pH of alkaline urines (22), but in the current study this effect was not evaluated. Some limitations of the current study were the small size of patients in the two groups and lack of cooperation by some patients and their parents. However, due to these reasons, further studies, especially prospective ones with larger sample sizes should be conducted to evaluate the efficacy of ascorbic acid supplementation in the control of UTI symptoms.

Acknowledgements

Footnote

References

  • 1.

    Yang J, Chen G, Wang D, Chen M, Xing C, Wang B. Low serum 25-hydroxyvitamin D level and risk of urinary tract infection in infants. Medicine (Baltimore). 2016;95(27). e4137. doi: 10.1097/MD.0000000000004137. [PubMed: 27399128]. [PubMed Central: PMC5058857].

  • 2.

    Williams GJ, Craig JC, Carapetis JR. Preventing urinary tract infections in early childhood. In: Williams GJ, Craig JC, Carapetis JR, editors. Hot Topics in Infection and Immunity in Children IX. New York: Springer; 2013. p. 211-8.

  • 3.

    Shiva F, Ghanaie R, Shirvani F, Armin S, Tabatabaei SR, Fahimzad SA, et al. Pattern of Antibiotic Usage in Children Hospitalized for Common Infectious Diseases. Arch Pediatr Infect Dis. 2018;6(1).

  • 4.

    Abdinia B, Mohkam M, Karimi A, Alikhah F. Prevalence Rate of Urinary Tract Infection and Disorder of Urinary Profiles in the 7-12 Years Old Healthy Children in Tabriz, Iran. Arch Pediatr. 2013;2(2).

  • 5.

    Pourzare M, Derakhshan S, Roshani D. Distribution of Uropathogenic Virulence Genes in Escherichia coli Isolated from Children with Urinary Tract Infection in Sanandaj, Iran. Arch Pediatr Infect Dis. 2017;In press(In press). doi: 10.5812/pedinfect.41995.

  • 6.

    Woei FJ, van der Starre WE, Tesselaar ME, Garcia Rodriguez P, van Nieuwkoop C, Bertina RM, et al. Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections. Thromb Res. 2014;133(5):799-803. doi: 10.1016/j.thromres.2014.03.007. [PubMed: 24657035].

  • 7.

    Christ-Libertin C, Black S, Latacki T, Bair T. Evidence-based prevent catheter-associated urinary tract infections guidelines and burn-injured patients: a pilot study. J Burn Care Res. 2015;36(1):e1-6. doi: 10.1097/BCR.0000000000000193. [PubMed: 25501781].

  • 8.

    Sharifian M, Sharifian S. Diagnostic challenges in Urinary Tract Infections in Children. Arch Pediatr Infect Dis. 2015;3(2). doi: 10.5812/pedinfect.21386.

  • 9.

    Jahanpour S, Ghazisaidi K, Davoodi H, Mazandarani M, Samet M, Jahanpour N, et al. Antimicrobial effects of folk medicinal plants from the North of Iran against Mycobacterium tuberculosis. Arch Pediatr Infect Dis. 2015;3(3 TB).

  • 10.

    Yousefi P, Dorreh F, Gazerani N. Effect of ablution the genital area on result of urine culturing among 3-12 years old girls referring to Amir Kabir hospital, Arak, Iran. Arch Clin Pediatr Infect Dis. 2010;5(3):133-6.

  • 11.

    Root-Bernstein R, Fewins J, Rhinesmith T, Koch A, Dillon PF. Enzymatic recycling of ascorbic acid from dehydroascorbic acid by glutathione-like peptides in the extracellular loops of aminergic G-protein coupled receptors. J Mol Recognit. 2016;29(7):296-302. doi: 10.1002/jmr.2530. [PubMed: 26749062].

  • 12.

    Yousefichaijan P, Rezagholizamenjany M, Dorreh F, Rafiei M, Taherahmadi H, Arjm A, et al. Serum zinc levels in children with and without nephrolithiasis. Current Pediatric Research. 2017;21(4):586-90.

  • 13.

    Nseir W, Taha M, Nemarny H, Mograbi J. The association between serum levels of vitamin D and recurrent urinary tract infections in premenopausal women. Int J Infect Dis. 2013;17(12):e1121-4. doi: 10.1016/j.ijid.2013.06.007. [PubMed: 23911156].

  • 14.

    Montorsi F, Gandaglia G, Salonia A, Briganti A, Mirone V. Effectiveness of a combination of cranberries, Lactobacillus rhamnosus, and vitamin C for the management of recurrent urinary tract infections in women: results of a pilot study. Eur Urol. 2016;70(6):912-5.

  • 15.

    Yousefichaijan P, Naziri M, Taherahmadi H, Kahbazi M, Tabaei A. Zinc Supplementation in Treatment of Children With Urinary Tract Infection. Iran J Kidney Dis. 2016;10(4):213-6. [PubMed: 27514768].

  • 16.

    Yousefi P, Firouzifar M, Cyrus A. Does hydrochlorothiazide prevent recurrent urinary tract infection in children with idiopathic hypercalciuria? J Pediatr Urol. 2013;9(6 Pt A):775-8. doi: 10.1016/j.jpurol.2012.09.008. [PubMed: 23131530].

  • 17.

    Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest. 2017;151(6):1229-38.

  • 18.

    Zarinfar N, Sarmadian H, Sirous A, Daneshmand MA, Pirasteh SH. The Effect of Vitamin C on the Recovery of Symptoms due to Pyelonephrities. Arak Med Univ J. 2009;12(46):65-72.

  • 19.

    Ranjbar R, Memariani H, Sorouri R. Molecular Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae Strains Isolated from Children with Urinary Tract Infections. Arch Pediatr Infect Dis. 2016;5(2). doi: 10.5812/pedinfect.39000.

  • 20.

    Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, Farthing CA, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J transl med. 2014;12(1):32.

  • 21.

    Yousefichaijan P, Kahbazi M, Rasti S, Rafeie M, Sharafkhah M. Vitamin E as adjuvant treatment for urinary tract infection in girls with acute pyelonephritis. Iran J Kidney Dis. 2015;9(2):97-104. [PubMed: 25851287].

  • 22.

    Yousefi Chaijan P, Sharafkhah M. A Comparison Between Bacterial Resistance to Common Antibiotics in Breast-Fed and Bottle-Fed Female Infants With Urinary Tract Infection. Arch Clin Pediatr Infect Dis. 2012;7(4):113-5. doi: 10.5812/archcid.15090.

  • COMMENTS

    LEAVE A COMMENT HERE: